Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21+/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA).-MedSci.cn

Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21+/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA).

Kasi, A; Diaz, F; Al-Rajabi, RMT; Baranda, JC; Carroll, E; Belcher, C; Olyaee, M; Rastogi, A; Schmitt, T; Kumer, S; Nawabi, A; Pathak, HB; Godwin, AK; Markiewicz, M; Sun, WJ

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务